N4 Pharma PLC Filing of further Nuvec® patent application (4038H)
15 Noviembre 2018 - 1:00AM
UK Regulatory
TIDMN4P
RNS Number : 4038H
N4 Pharma PLC
15 November 2018
15 November 2018
N4 Pharma Plc
("N4 Pharma" or the "Company")
Filing of further Nuvec(R) patent application
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing a novel delivery system for vaccines and cancer
treatments, is pleased to announce the filing of its Patent
Cooperation Treaty ("PCT") patent application for its novel
delivery system, Nuvec(R).
Nuvec(R) is licensed by the Company from the University of
Queensland under their silica nanoparticle patent application,
which is currently under prosecution before various national patent
offices. The patent application that was filed by the Company is
based on improvements made to the manufacturing process, as the
Company has scaled up production alongside specific examples of how
Nuvec(R) can be used to improve delivery of nucleic acids.
The Company's new PCT patent application claims priority from
the Company's United Kingdom patent application number 1718817.8.
The PCT application will publish approximately 18 months from the
priority date of 14 November 2017. Therefore publication is
expected on or shortly after 14 May 2019. National phase entry is
due 30 months from the priority date, in most countries. The
national phasing deadline is therefore expected to be 14 May
2020.
Nigel Theobald, CEO of N4 Pharma commented:
"Having strong intellectual property for Nuvec(R) is important
for commercial outlicensing and this new PCT patent application not
only strengthens the intellectual property rights around Nuvec(R)
but, if granted, would provide an extra 30 months protection for
Nuvec(R) after expiry of the in licensed IP which, if granted,
would likely expire in April 2036.
"As our work on Nuvec(R) progresses,we anticipate that
subsequent patent applications will be filed to extend the
protection for Nuvec(R) even further."
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Alma PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Virginia Bull/Asha
Chotai
Alma PR
Josh Royston Tel: +44(0)778 090 1979
Robyn Fisher Tel: +44(0)754 070 6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R)
Nuvec(R) has shown to be capable of loading and delivering mRNA
and pDNA into cells to the required level needed to generate an
immune response. Further work will be undertaken for the direct
loading and delivery of peptides and proteins using Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immune response. As
these products progress through pre clinical and clinical programs
N4 will receive up front and milestone payments and ultimately
royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBCBDBDGBBGIS
(END) Dow Jones Newswires
November 15, 2018 02:00 ET (07:00 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024